Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

BACKGROUND. In the U.S., the addition of bevacizumab to first‐line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality‐adjusted life years (QALYs) at an incremental cost‐effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value fo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Goldstein, Daniel A., Chen, Qiushi, Ayer, Turgay, Chan, Kelvin K. W., Virik, Kiran, Hammerman, Ariel, Brenner, Baruch, Flowers, Christopher R., Hall, Peter S.
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2017
Assuntos:
Health Outcomes and Economics of Cancer Care
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469597/
https://ncbi.nlm.nih.gov/pubmed/28592621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0455
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares